These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15923670)

  • 1. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.
    Flink HJ; Sprengers D; Hansen BE; van Zonneveld M; de Man RA; Schalm SW; Janssen HL;
    Gut; 2005 Nov; 54(11):1604-9. PubMed ID: 15923670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.
    Sonneveld MJ; Zoutendijk R; Flink HJ; Zwang L; Hansen BE; Janssen HL
    Clin Infect Dis; 2013 Jan; 56(1):100-5. PubMed ID: 23042976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Bigot G; Haagmans BL; Janssen HL
    J Clin Virol; 2008 Jun; 42(2):160-4. PubMed ID: 18359663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
    Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
    Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo.
    Hansen BE; Rijckborst V; Ter Borg MJ; Janssen HL
    J Med Virol; 2011 Nov; 83(11):1917-23. PubMed ID: 21915866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flares during long-term entecavir therapy in chronic hepatitis B.
    Chi H; Arends P; Reijnders JG; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Oo YH; Petersen J; van Bommel F; de Knegt RJ; Santantonio TA; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen BE; Janssen HL;
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1882-1887. PubMed ID: 27008918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The good and evil of flare: flares in hepatitis B virus chronic hepatitis.
    Massetto B; Menzaghi B; Giambelli C; Antinori S; Milazzo L
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):821-3. PubMed ID: 17700272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
    ter Borg MJ; van Zonneveld M; Zeuzem S; Senturk H; Akarca US; Simon C; Hansen BE; Haagmans BL; de Man RA; Schalm SW; Janssen HL;
    Hepatology; 2006 Sep; 44(3):721-7. PubMed ID: 16941701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
    Buster EH; Hansen BE; Buti M; Delwaide J; Niederau C; Michielsen PP; Flisiak R; Zondervan PE; Schalm SW; Janssen HL;
    Hepatology; 2007 Aug; 46(2):388-94. PubMed ID: 17604363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
    Vassiliadis T; Tziomalos K; Patsiaoura K; Zagris T; Giouleme O; Soufleris K; Grammatikos N; Theodoropoulos K; Mpoumponaris A; Dona K; Zezos P; Nikolaidis N; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1582-8. PubMed ID: 17683500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.